Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $25 and keeps a Buy rating on the shares following the fiscal Q2 report. The company will now present data from both batoclimab Phase 3 thyroid eye disease trials in 2026, the analyst tells investors in a research note. Citi sees Roivant’s investor day on December 11 laying a catalyst path for the shares in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: